C4 Therapeutics (NASDAQ: CCCC) CMO sells 10,000 shares of stock

Rhea-AI Filing Summary

C4 Therapeutics Chief Medical Officer Leonard Reyno reported an open-market sale of company stock. On January 16, 2026, he sold 10,000 shares of C4 Therapeutics, Inc. common stock at a price of $2.22 per share, as shown by transaction code "S" for a disposition. After this trade, he directly beneficially owns 156,382 shares of the company’s common stock.

Insider Trade Summary

Net Seller: 10,000 shares ($22,200)

Net Sell 1 txn

Insider REYNO LEONARD

Role Chief Medical Officer

Sold 10,000 shs ($22K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$2.22	$22K

Holdings After Transaction: Common Stock — 156,382 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

REYNO LEONARD

(Last) (First) (Middle)

C/O C4 THERAPEUTICS, INC.

490 ARSENAL WAY #120

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
C4 Therapeutics, Inc. [ CCCC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		S		10,000	D	$2.22	156,382	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Shagha Russell, Attorney-in-Fact	01/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did C4 Therapeutics (CCCC) report in this Form 4?

The filing reports that Chief Medical Officer Leonard Reyno sold 10,000 shares of C4 Therapeutics, Inc. common stock on January 16, 2026.

At what price were the C4 Therapeutics (CCCC) shares sold by the CMO?

The 10,000 shares of common stock were sold at a price of $2.22 per share.

How many C4 Therapeutics (CCCC) shares does the CMO own after the sale?

Following the reported transaction, Chief Medical Officer Leonard Reyno directly beneficially owns 156,382 shares of C4 Therapeutics common stock.

What is Leonard Reyno’s role at C4 Therapeutics (CCCC)?

Leonard Reyno is identified in the filing as an officer of C4 Therapeutics, serving as the company’s Chief Medical Officer.

Was this C4 Therapeutics (CCCC) Form 4 filed for one reporting person or multiple?

The document indicates that the Form 4 was filed by one reporting person, namely Chief Medical Officer Leonard Reyno.

What type of security was involved in the C4 Therapeutics (CCCC) insider transaction?

The transaction involved common stock of C4 Therapeutics, Inc., reported in Table I for non-derivative securities.